266 related articles for article (PubMed ID: 25491391)
1. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.
Reinders ME; Bank JR; Dreyer GJ; Roelofs H; Heidt S; Roelen DL; Al Huurman V; Lindeman J; van Kooten C; Claas FH; Fibbe WE; Rabelink TJ; de Fijter JW
J Transl Med; 2014 Dec; 12():331. PubMed ID: 25491391
[TBL] [Abstract][Full Text] [Related]
2. Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.
Reinders ME; Dreyer GJ; Bank JR; Roelofs H; Heidt S; Roelen DL; Zandvliet ML; Huurman VA; Fibbe WE; van Kooten C; Claas FH; Rabelink TJ; de Fijter JW
J Transl Med; 2015 Nov; 13():344. PubMed ID: 26537851
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
Trials; 2016 Feb; 17():92. PubMed ID: 26888217
[TBL] [Abstract][Full Text] [Related]
4. Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study.
Pan GH; Chen Z; Xu L; Zhu JH; Xiang P; Ma JJ; Peng YW; Li GH; Chen XY; Fang JL; Guo YH; Zhang L; Liu LS
Oncotarget; 2016 Mar; 7(11):12089-101. PubMed ID: 26933811
[TBL] [Abstract][Full Text] [Related]
5. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study.
Peng Y; Ke M; Xu L; Liu L; Chen X; Xia W; Li X; Chen Z; Ma J; Liao D; Li G; Fang J; Pan G; Xiang AP
Transplantation; 2013 Jan; 95(1):161-8. PubMed ID: 23263506
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
[TBL] [Abstract][Full Text] [Related]
7. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study.
Reinders ME; de Fijter JW; Roelofs H; Bajema IM; de Vries DK; Schaapherder AF; Claas FH; van Miert PP; Roelen DL; van Kooten C; Fibbe WE; Rabelink TJ
Stem Cells Transl Med; 2013 Feb; 2(2):107-11. PubMed ID: 23349326
[TBL] [Abstract][Full Text] [Related]
8. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
Tan J; Wu W; Xu X; Liao L; Zheng F; Messinger S; Sun X; Chen J; Yang S; Cai J; Gao X; Pileggi A; Ricordi C
JAMA; 2012 Mar; 307(11):1169-77. PubMed ID: 22436957
[TBL] [Abstract][Full Text] [Related]
9. New Recipes With Known Ingredients: Combined Therapy of Everolimus and Low-dose Tacrolimus in De Novo Renal Allograft Recipients.
Santos T; Santos L; Macário F; Romãozinho C; Alves R; Campos M; Mota A
Transplant Proc; 2015 May; 47(4):906-10. PubMed ID: 26036483
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stromal cells in renal transplantation: opportunities and challenges.
Casiraghi F; Perico N; Cortinovis M; Remuzzi G
Nat Rev Nephrol; 2016 Apr; 12(4):241-53. PubMed ID: 26853275
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
12. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
14. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
15. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
17. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
18. Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation.
Plock JA; Schnider JT; Zhang W; Schweizer R; Tsuji W; Kostereva N; Fanzio PM; Ravuri S; Solari MG; Cheng HY; Rubin PJ; Marra KG; Gorantla VS
Transplantation; 2015 Sep; 99(9):1765-73. PubMed ID: 26102613
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients.
Brunkhorst LC; Fichtner A; Höcker B; Burmeister G; Ahlenstiel-Grunow T; Krupka K; Bald M; Zapf A; Tönshoff B; Pape L
PLoS One; 2015; 10(9):e0135439. PubMed ID: 26407177
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis.
Murphy GJ; Waller JR; Sandford RS; Furness PN; Nicholson ML
Br J Surg; 2003 Jun; 90(6):680-6. PubMed ID: 12808614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
